Mainz, Germany, 15 September 2020 (GLOBE NEWSWIRE) –
MAINZ, GERMANY, 15 September 2020 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the company”) today announced that it will receive a grant of up to 375 million euros from an initiative of the German Federal Ministry of Education and Research (BMBF) to accelerate the progression of SARS-CoV-2 vaccines. BioNTech will use BMBF’s gradual investment to contribute to BNT162’s mNA vaccine program, which is developed in conjunction with Pfizer Inc. partners. and Fosun Pharma, respectively. The objective of this initiative is to expand the production and progression functions of vaccines in Germany, as well as to increase the number of participants in complex clinical trials. The BNT162 vaccination programme is one of 3 programmes developed through the BMBF initiative, which will provide one of 750 million euros to its recipients of the investment.
“We are grateful for the vital help of BMBF, which is helping us deliver a safe and effective vaccine as soon as possible after regulatory approval. Investment is a vital contribution to driving the progression and expansion of our COVID-19 vaccine production functions in Germany. It underscores the enormous importance of our project in finding a lasting solution to control the pandemic,” said Ugur Sahin, M. D. , CEO and co-founder of BioNTech.
BioNTech will use the grant investment to support its COVID-19 BNT162 vaccine program as a component of the funded allocation to advance clinical evaluation and prospective marketing approval as soon as possible. Pfizer will continue to independently finance its percentage of BNT162 progression prices without this or another investment government.